Myopia

Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10

Retrieved on: 
Thursday, August 4, 2022 - 1:00pm
GLOBE, Presbyopia, MAP, Myopia, Company, Review, NASDAQ, Therapy, Mydriasis, Pharmaceutical industry

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.

Key Points: 
  • NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.
  • Following the release, Eyenovia management will host a conference call to review the financial and operating results.
  • The conference call is scheduled to begin at 4:30pm ET on Wednesday, August 10, 2022.
  • A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com .

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

Retrieved on: 
Wednesday, July 27, 2022 - 1:00pm
CA, Strategic planning, Allergan, Corporation, GLOBE, Intelligence, Bausch & Lomb, U.S. Securities and Exchange Commission, Forward-looking statement, Myopia, NDA, Marketing, Bayer, Board, COVID-19, NASDAQ, Pfizer, Mydriasis, Technology, Company, Patient, Presbyopia, Therapy, Pharmaceutical industry, Management, DRS

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Companys new Chief Executive Officer, effective August 1, 2022.

Key Points: 
  • NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Companys new Chief Executive Officer, effective August 1, 2022.
  • Mr. Rowe has also been appointed to Eyenovias Board of Directors, increasing the Board to nine seats following recent appointments of Drs.
  • Eyenovias current Chief Executive Officer, Dr. Sean Ianchulev, previously announced that he will be transitioning to Chairman of the companys Board.
  • For the past four years, we have benefited from Michaels diverse ophthalmic industry experience, and we believe he is the ideal candidate to shepherd Eyenovia through this exciting new chapter in the Companys evolution, stated Dr. Sean Ianchulev, Eyenovias Chief Executive Officer and Chief Medical Officer.

Leading Asian AR startup Rokid Expands into the North American Market

Retrieved on: 
Friday, July 22, 2022 - 2:00pm
Entertainment, Consumer Electronics, Other Entertainment, Technology, General Entertainment, Other Technology, Electronic Games, Algorithm, Investment, Lens (anatomy), GMV, Industry, VCS, G, Myopia, Xbox, Marketing, Computer, Multimedia, Amazon (company), End, PlayStation, Kickstarter, Light, Bacon roll, AR, Online shopping, Tmall, Pacific Ocean, Zooma, Amazon

Leading AR company Rokid has taken advantage of Amazon Prime Day deals to sell its consumer-grade AR glasses, the Rokid Air resulting in a push into the North American market.

Key Points: 
  • Leading AR company Rokid has taken advantage of Amazon Prime Day deals to sell its consumer-grade AR glasses, the Rokid Air resulting in a push into the North American market.
  • With the Prime Day event over, Rokid is aiming to promote their Rokid Air to a wider range of consumers.
  • View the full release here: https://www.businesswire.com/news/home/20220722005185/en/
    The Rokid Air are the first pair of consumer-grade AR devices launched by Rokid under $500.
  • The outstanding sales figures during Amazon Prime Day is an important milestone in the companys expansion into the North American market.

Hoot and Haag-Streit Announce Partnership to Modernize Education of Progressive Myopia in Kids

Retrieved on: 
Wednesday, July 20, 2022 - 1:30pm
Eye, Education, VP, ECP, Parent, Myopia, OH, Multimedia, Technology, Patient, Hoot, Automation, Child, Toy

PRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Hoot Myopia Care.com (owned by Hoot Health, Inc.), a digital marketing automation platform for eye doctors practicing myopia management, announced that Haag-Streit, a leader in developing medical devices in the field of eye care, will partner with Hoot to deliver specific programs for ECPs to diagnose, educate and demonstrate myopia management and monitoring in kids.

Key Points: 
  • PRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Hoot Myopia Care.com (owned by Hoot Health, Inc.), a digital marketing automation platform for eye doctors practicing myopia management, announced that Haag-Streit, a leader in developing medical devices in the field of eye care, will partner with Hoot to deliver specific programs for ECPs to diagnose, educate and demonstrate myopia management and monitoring in kids.
  • Haag-Streit will work with Hoot to co-produce educational digital content and myopia specific workflows and integrate it into the Hoot ecosystem.
  • ", said Dr. Shefali Miglani, Chief Medical Officer of Hoot Myopia Care.com.
  • Learn more: https://www.haag-streit.com/haag-streit-usa/
    Hoot is a marketing automation platform for eye care professionals to help them grow and scale their myopia management practice.

Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

Retrieved on: 
Monday, July 18, 2022 - 1:00pm
Research, Â, Manufacturing & Service Operations Management, U.S. Securities and Exchange Commission, Solution, Therapy, Engineering, GLOBE, Forward-looking statement, Presbyopia, Technology, Insurance, Marketing, NASDAQ, Organization, Silicon, COVID-19, Microcline, Company, CGMP, PMA, CA, Senior, Bausch & Lomb, Myopia, Mydriasis, Pharmaceutical industry, Management, Medical device

With our Redwood City facility now operational, Eyenovia has internal manufacturing capabilities to complement our existing contract manufacturing partners, stated Michael Rowe, Chief Operating Officer of Eyenovia.

Key Points: 
  • With our Redwood City facility now operational, Eyenovia has internal manufacturing capabilities to complement our existing contract manufacturing partners, stated Michael Rowe, Chief Operating Officer of Eyenovia.
  • Eyenovia also announced today the appointment of Bren Kern as the Companys new Senior Vice President of Manufacturing and Operations.
  • I look forward to contributing to the team and championing our internal manufacturing and engineering operations to help bring these exciting solutions to market.
  • Mr. Kern has spent his career helping companies transition from research and development entities into scaled commercial manufacturing organizations.

Global Ophthalmic Devices Market (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 15, 2022 - 5:04pm
Optical, Health, Surgery, Medical Devices, Research report, Eye, World Health Organization, Severe cognitive impairment, Patient, WHO, Vance DeGeneres, CAGR, Review, Astigmatism, Presbyopia, Far-sightedness, Diabetic retinopathy, Ophthalmology, Amblyopia, Approximation error, Eastern, Cataract, COVID-19, Strabismus, Growth, Prevalence, Visual impairment, Myopia, Glaucoma, Pharmaceutical industry, Liquor

The Vision Correction Devices or corrective lenses are used to aid and improve vision for those with common refractive errors like myopia, hypermetropia, astigmatism, and presbyopia.

Key Points: 
  • The Vision Correction Devices or corrective lenses are used to aid and improve vision for those with common refractive errors like myopia, hypermetropia, astigmatism, and presbyopia.
  • Thousands of ophthalmic clinical consultations and operations have been cancelled as a result of the recent pandemic lockdown, potentially causing lasting and substantial eyesight damage to patients.
  • Furthermore, according to a research article titled "The impact of COVID-19 pandemic on ophthalmology services: are we ready for the aftermath?"
  • Hence, the high number of cases is likely to create demand for advanced products and services, thereby boosting the market growth.

Kubota Vision Announces Publication in Scientific Reports; Effects of Using Projected Peripheral Myopic Defocus

Retrieved on: 
Thursday, July 14, 2022 - 4:30pm
Medical Devices, Health, Clinical Trials, Research, Science, Optical, Stargardt disease, Myopia, Retina, Diabetic retinopathy, Vision Research, Engineering, MVA, OCT, Glass, Psychology, View, Patient, CEO, CooperVision, Adult, MD, Food, Scientific Reports, Population, Medicine, Springer Nature, FDA, Research, Food and Drug Administration, Doctor of Philosophy, PLOS, University, Pharmaceutical industry, Medical device

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.
  • This was a 4-month prospective clinical study conducted at MVA to investigate the effects of using projected peripheral myopic defocus in a benchtop optical system.
  • The primary objective of the study was to assess the central axial length and cycloplegic refractive changes using a novel optical system and myopic defocus stimulus design.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

TQSKY launches T1 Smart Glasses for a Portable Entertainment Experience Like Never Before

Retrieved on: 
Thursday, July 7, 2022 - 12:05pm
AR, Nintendo Switch, CEO, Research, Technology, PlayStation 5, Smartglasses, PlayStation, Bass, Kickstarter, Element, Industry, Xbox Series X and Series S, Certification, Privacy, Tablet, Multimedia, Light, Myopia, Television, Cassette tape

NEW YORK, July 7, 2022 /PRNewswire/ -- TQSKY, a newcomer in the consumer technology offering world class experiences, is releasing the world's first audio-visual glasses, TQSKY T1, on Kickstarter today. Slim, light, and fashionable, these AR/XR glasses seek to change how consumers view entertainment options on the go or in the comfort of their own homes.

Key Points: 
  • NEW YORK, July 7, 2022 /PRNewswire/ -- TQSKY, a newcomer in the consumer technology offering world class experiences, is releasing the world's first audio-visual glasses, TQSKY T1, on Kickstarter today.
  • Slim, light, and fashionable, these AR/XR glasses seek to change how consumers view entertainment options on the go or in the comfort of their own homes.
  • The TQSKY T1 is also adjustable for 0-600 myopia.
  • Immersive and CD-grade audio quality: The only audiovisual glasses with Hi-Res sound quality certification that does not require headphones to enjoy high-quality audio.

Worldwide Lens Industry to 2027 - Featuring Hoya, Eastman Kodak, Carl Zeiss and Fielmann Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022 - 5:52pm
Health, Optical, Wind, Glass, Pollution, Far-sightedness, Severe cognitive impairment, COVID-19, Industry, Lens, Profile, Life expectancy, Digital, Glaucoma, Risk, UV, Presbyopia, Cataract, Infection, Maintenance, Macular degeneration, Eye, Diabetic retinopathy, Myopia, Microscope, Camera, Potash, Fused quartz

They also offer protection to the eyes from environmental pollutants such as debris, wind and UV rays.

Key Points: 
  • They also offer protection to the eyes from environmental pollutants such as debris, wind and UV rays.
  • What are the various stages in the value chain of the global glass lens industry?
  • What is the structure of the global glass lens industry and who are the key players?
  • What is the degree of competition in the global glass lens industry?